This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

Professionals 212 Users Online

Intravitreal (IVT) Injectable Market

Global Market Study on Intravitreal (IVT) Injectables: Chronic Retinal Conditions to Uplift Sales of Anti-VEGF IVT Injectables

Intravitreal Injectables Market Segmented By Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Endophthalmitis Indication in Anti-VEGF, Corticosteroids, Antibiotics, Antivirals, Antifungals Drug Class

Intravitreal (IVT) Injectable Market Outlook (2022 - 2028)

Intravitreal injection is a safe and efficient therapeutic option for retinal diseases such as diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusion, and others. Growing retinal problems are likely to drive the global intravitreal injectable market at a rapid pace throughout the forecast period. The Global Intravitreal (IVT) Injectable Market is estimated to reach $23,814.3 million by 2028, having a CAGR of 4.9%.

Intravitreal (IVT) Injectable Market Size (2022)

US$ 17,849.5 Mn

Projected Market Value (2028)

US$ 23,814.3 Mn

Global Market Growth Rate (2022 - 2028)

4.9% CAGR

Share in parent market

7.4%

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Intravitreal (IVT) Injectable Market Demand Analysis (2013-2021) v/s Market Outlook (2022 - 2028)

The vitreo-retinal disease has been a significant reason for blindness and visual impairment all over the world. Many people suffer from retinal problems, which frequently result in vision loss or total blindness. Intravitreal injection is a secure and convenient treatment option for retinal diseases such as diabetic retinopathy, macular degeneration, endophthalmitis, retinal vein occlusion, and others. Growing retinal problems are likely to drive the global intravitreal injectable market at a significant rate throughout the forecast period.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

Key Drivers to the Intravitreal (IVT) Injectable Market

  • Increasing Incidence of Retinal Diseases

The vitreo-retinal disease has been the main reason for visual impairment and blindness all over the world. Intravitreal (IVT) injectables are an important part of the therapy of retinal diseases. Patients with chronic retinal illnesses require recurring intravitreal (IVT) injectable doses, and hence the intravitreal (IVT) injectables market is expected to grow substantially over the projected period.

  • Development of Novel Drugs

Many pharmaceutical companies are concentrating on developing novel medications to treat intraocular disorders and address patients' unmet requirements. Several market players are working on treatments for various purposes that will most likely be delivered via intravitreal (IVT) injectables.

intravitreal-ivt-injectable-market

  • Increased Demand for Intravitreal (IVT) Injectables

Intravitreal (IVT) Injectables are becoming increasingly popular among doctors since these are more effective and safer than the other therapy alternatives for intraocular diseases. Intravitreal (IVT) injectables are utilized to treat a wide range of retinal disorders. It could be utilized to administer anticancer, antivascular endothelial growth factor, anti-inflammatory, antibacterial, surgical gases, and the other medicinal substances. Intravitreal (IVT) injectables efficiently cure retinal problems and are being widely utilized for treatments of intraocular diseases, hence the increasing demand for Intravitreal (IVT) Injectables market is expected to rise rapidly in the near future.

  • Increasing Adoption of Anti-VEGF Therapies

Anti-VEGF therapies are generally used to treat chronic retinal illnesses such as diabetic retinopathy, macular degeneration, retinal vein occlusion, and others. The increasing frequency of these severe conditions has led to an increase in the adoption of anti-VEGF therapies, which result in a significant need for intravitreal (IVT) injectables. The increasing adoption of anti-VEGF will fuel market growth going forward.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Restraints to the Intravitreal (IVT) Injectable Market

  • “Risks and Complications Associated with Intravitreal (IVT) Injectables”

Intravitreal (IVT) Injectables are becoming increasingly popular among doctors because they are safer and more effective. However, the necessity of repeated intravitreal injections, as well as the risks or problems associated with injectables, such as infection and inflammation in the eye, retinal detachment, and vitreous hemorrhage, are expected to restrain the global market in the future.

Prerna Shiv

Prerna Shiv
Client Partner

Let's Connect

Conect me to identify wining opportunities

Ask An Expert
I'm Available

Impact of Covid-19 Pandemic

“Reduction in Clinic Visits and Intravitreal (IVT) Injectables”

The global economy has been damaged by the Covid-19 pandemic. Due to lockdowns and an overwhelming number of covid-19 patients, attendance at scheduled clinic appointments and Intravitreal (IVT) Injectables had decreased. However, the situation improved when the covid-19 restrictions were lifted in September 2021, and demand for intravitreal (IVT) injectables increased once again.

Competitive Landscape

The Intravitreal (IVT) Injectable Market is highly competitive, with the presence of global giants. To expand their product portfolio footprint in the intravitreal injectables market, prominent players are implementing organic and inorganic methods such as product launches, collaboration, product agreements, etc.

  • In July 2018, Roche announced the first successful phase II study of a long-acting delivery device for the treatment of neovascular (“wet”) age-related macular degeneration (nAMD).
  • In August 2018, Regeneron Pharmaceuticals, Inc. announced that its EYLEA® (aflibercept) Injection was approved by the U.S. Food and Drug Administration (FDA).

Intravitreal (IVT) Injectable Market Industry Report Scope

Attribute

Details

Forecast Period

2022 - 2028

Historical Data Available for

2013-2021

Market Analysis

US$ Mn/Bn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Key Countries Covered

  • U.S.
  • Canada
  • Germany
  • Italy
  • France
  • U.K.
  • Spain
  • Russia
  • India
  • China
  • Japan
  • UAE
  • Australia

Key Market Segments Covered

By Indication

Key Companies Profiled

  • Regeneron Pharmaceuticals, Inc.
  • Bausch & Lomb
  • Novartis AG
  • Allergan
  • Alimera Sciences
  • ThromboGenics, Inc. 
  • Bristol-Myers Squibb Company
  • Other

Customization & Pricing

Available upon Request

Intravitreal (IVT) Injectable Market Categorization

Intravitreal (IVT) Injectable Market by Indication

  • Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Endophthalmitis
  • Others

Intravitreal (IVT) Injectable Market by Drug Class

  • Anti-VEGF
  • Corticosteroids
  • Antibiotics
  • Antivirals
  • Antifungals

Intravitreal (IVT) Injectable Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

- Companies Covered in This Report -

  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals, Inc.
  • Bausch & Lomb
  • Novartis AG
  • Allergan
  • Alimera Sciences
  • ThromboGenics, Inc.
  • Bristol-Myers Squibb Company

- Frequently Asked Questions -

In 2022, the Intravitreal (IVT) Injectable Market stands at USD 17,849.5 million, and it is expected to reach USD 23,814.3 million by 2028 at a CAGR of 4.9%.

Intravitreal (IVT) Injectable Market exhibited a CAGR of 4.4% between 2013 and 2021.

Risks and complications associated with Intravitreal (IVT) Injectables are the key restraints in the Intravitreal (IVT) Injectable Market.

Increasing prevalence Of Retinal Diseases and the increased demand for Intravitreal (IVT) Injectables are the key factors driving the growth of the market.

Regeneron Pharmaceuticals Inc., Bausch & Lomb, Novartis AG, and Allergan are among the top players in the market.

Google translate